COPENHAGEN, Denmark & ST. LOUIS--(BUSINESS WIRE)--The BioAg Alliance, Monsanto’s and Novozymes’ collaboration to improve crop harvests through products containing naturally-occurring microbes, today announced an updated research and development pipeline.
Among the highlights is the Corn BioYield 2 project, which advanced to Phase 4 (pre-commercial) in The BioAg Alliance R&D pipeline and is expected to be branded as Acceleron B-360 ST, pending regulatory approvals. Acceleron B-360 ST promotes symbiosis between microbes and corn plants to strengthen root systems and increase plants’ access to nutrients. Acceleron B-360 ST will be used in combination with the successful Acceleron B-300 SAT, which was introduced in 2017 and used by U.S. farmers on more than 4 million corn acres in its first year. Acceleron B-300 SAT is expected to be applied to between 8-10 million acres in 2018, while Acceleron B-360 ST is scheduled to enter the market in 2019.
Biological seed treatments such as Acceleron B-300 SAT help plants build healthy root systems, which enable more efficient uptake of nutrients into the plant. The increase in nutrient uptake results in a decrease in the release of those nutrients into the environment, either via runoff into water supplies or into the air. The increases in plant biomass can help to sequester carbon into the soil, particularly in microbes that promote root development. The result is pulling carbon dioxide out of the air and storing it in the soil.
The BioAg Alliance also announced the achievement of a significant milestone in the Corn BioYield 3 project. Over the past four years, researchers have screened thousands of microbes across multiple sites to find out which microbes deliver the highest increase in crop yield. A small group of top performers have now been selected for commercial evaluation and development.
“The BioAg Alliance sets a very high bar for success through a challenging and unique field testing program where microbes are selected by consistently outperforming thousands of other microbes in real application conditions across several years and in diverse environments,” says Tom Adams, Monsanto Vice President of Global Biotechnology. “Our field testing program is not only generating novel product leads, but also providing insight into microbe and environment relationships, which will help lead to precision agriculture solutions in the future.”
Projects in the soy pipeline also progressed. The Soy BioYield 2 project is expected to lead to a product for the North American market and a product for South America. Both products contain bacteria that increase soybeans’ uptake of nitrogen leading to improved plant health and more bountiful harvests. The Soy BioNematicide project is researching a new biological way to control soybean cyst nematodes, a parasitic roundworm that attacks the roots of soybeans and is a devastating pest worldwide causing stunted growth and severe loss of yield. The project has now shown efficacy for four consecutive years.
“Nature’s toolbox of beneficial bacteria and fungi can help us produce healthier crops with higher yields while reducing the need for fertilizer and other chemicals,” says Ejner Bech Jensen, Novozymes’ Vice President for BioAg Research. “Our understanding of microbes and their symbiotic relationships with plants is evolving rapidly, and we have exciting products coming to market over the coming years in both the bioyield and biocontrol segments.”
In addition to the pipeline updates, The BioAg Alliance announced it is preparing for expansion into Europe. Today, The BioAg Alliance products are primarily sold in North and South America, but in 2019-20 the Alliance plans to launch products for growers of corn, oilseed rape and wheat in European markets. The products will mainly be based on Acceleron B-300 SAT and Acceleron B-360 ST technologies.
The BioAg Alliance biological products are derived from naturally-occurring microbes such as bacteria and fungi. The Alliance aims to produce bioyield products, which help plants with nutrient uptake, and biocontrol products, which help protect plants against pests and diseases. The products can be applied to seeds before planting, to soil in-furrow, or to growing crops. They can be used by farmers that grow broad-acre crops such as corn and soy, and on fruits and vegetables. Microbial products can increase crop yields and complement or replace agricultural chemicals and fertilizers, while helping farmers reduce the amount of CO2 produced from their land.
The BioAg Alliance 2018 pipeline update was announced as part of Monsanto’s annual pipeline update. For more information, go to www.monsanto.com/pipeline.
- Corn BioYield 2, expected to be branded as Acceleron B-360 ST pending regulatory approvals, harnesses the signal molecule LCO (lipo-chitooligosaccharide) that promotes beneficial plant-microbe interactions, such as symbiotic relationships between soil fungi and plants. Beneficial soil fungi colonizes the roots to increase the crop's ability to uptake nutrients and water. This project advanced to Phase 4 in The BioAg Alliance R&D pipeline.
- The Soy BioYield 2 project is based on the beneficial soil bacteria bradyrhizobium. The bacteria and the soybean plants enter a symbiotic relationship which increases nutrient uptake for the plant and increases yield. This project advanced to Phase 3 in The BioAg Alliance R&D pipeline.
- The Soy BioNematicide project is expected to provide an additional tool for growers to control nematodes, microscopic parasitic worms that damage plants. It shows activity against multiple nematode species, including the soybean cyst nematode. The Alliance will continue field tests to confirm efficacy in combination with a range of other chemical and biological seed treatments. This project advanced to Phase 3 in The BioAg Alliance R&D pipeline.
- The Corn BioYield 3 project – The BioAg Alliance is testing multiple microbial strains for a new corn inoculant. The Corn BioYield 3 project is anticipated to be the first product invented and developed from discovery to launch through The BioAg Alliance.
About The BioAg Alliance
First announced in December 2013, the BioAg Alliance is unique in the industry, bringing together Novozymes’ BioAg operations and capabilities within microbial discovery, development and production with Monsanto’s microbial discovery, advanced biology, field testing and commercial capabilities. The result is a comprehensive discovery, development and commercial collaboration to help farmers globally meet the challenge of producing more with less in a sustainable way – for the benefit of agriculture, consumers, the environment and society at large.
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com
About Monsanto Company
Monsanto is committed to bringing a broad range of solutions to help nourish our growing world. We produce seeds for fruits, vegetables and key crops - such as corn, soybeans, and cotton - that help farmers have better harvests while using water and other important resources more efficiently. We work to find sustainable solutions for soil health, help farmers use data to improve farming practices and conserve natural resources, and provide crop protection products to minimize damage from pests and disease. Through programs and partnerships, we collaborate with farmers, researchers, nonprofit organizations, universities and others to help tackle some of the world’s biggest challenges. To learn more about Monsanto, our commitments and our more than 20,000 dedicated employees, please visit monsanto.com. Follow our business on Twitter® at twitter.com/MonsantoCo.
Cautionary Statements Regarding Forward-Looking Information
Certain statements contained in this release are “forward-looking statements,” such as statements concerning the company’s anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts, as well as the pending transaction with Bayer Aktiengesellschaft (“Bayer”). These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: risks related to the pending transaction between the company and Bayer, including the risk that the regulatory approvals required for the transaction may not be obtained on the anticipated terms or time frame or at all, the risk that the other conditions to the completion of the transaction may not be satisfied, the risk that disruptions or uncertainties related to the pending transaction could adversely affect the company’s business, financial performance and/or relationships with third parties, and the risk that certain contractual restrictions during the pendency of the transaction could adversely affect the company’s ability to pursue business opportunities or strategic transactions; continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public understanding and acceptance of our biotechnology and other agricultural products; the success of the company's research and development activities; the outcomes of major lawsuits, including potential litigation related to the pending transaction with Bayer; developments related to foreign currencies and economies; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the levels of indebtedness, continued availability of capital and financing and rating agency actions; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters, accidents, and security breaches, including cybersecurity incidents, on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.
ALWAYS READ AND FOLLOW PESTICIDE LABEL DIRECTIONS. Acceleron is a registered trademark of Monsanto Technology LLC. ©2018 Monsanto Company.